Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2025 Mar 1;11(3):340-342.
doi: 10.1001/jamaoncol.2024.5648.

Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Nonrandomized Clinical Trial

Bradford S Hoppe  1 , Sarah A Milgrom  2 , Lindsay A Renfro  3   4 , Yue Wu  4 , Cindy L Schwartz  5 , Louis S Constine  6 , Kathleen M McCarten  7 , Kara M Kelly  8 , David Hodgson  9   10 , Sharon M Castellino  11 , Frank G Keller  11
Affiliations
Comment

Transplant-Free Salvage Therapy for Low-Risk Relapsed Pediatric Hodgkin Lymphoma: A Nonrandomized Clinical Trial

Bradford S Hoppe et al. JAMA Oncol. .
No abstract available

Plain language summary

This nonrandomized clinical trial reports outcomes for children with low-risk relapsed Hodgkin lymphoma treated with second-line chemotherapy and involved-field radiotherapy without autologous stem cell transplant.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Hoppe reported being a member of the scientific advisory committee for Merck and being contracted through the Children’s Oncology Group to the Mayo Clinic outside the submitted work. Dr Milgrom reported working as an unpaid consultant regarding positron emission tomography/computed tomography analyses for Bristol Myers Squibb. Dr Kelly reported grants from the National Cancer Institute during the conduct of the study; grants from Merck, nonfinancial support from BMS and Seagen (both provide study drug for an NCI-funded trial), and grants from the Department of Defense outside the submitted work. Dr Castellino reported personal fees from Seagen Inc during the conduct of the study and outside the submitted work, and personal fees from Bristol Myers Squibb outside the submitted work. No other disclosures were reported.

Comment on

Similar articles

See all similar articles

References

    1. Harker-Murray PD, Drachtman RA, Hodgson DC, Chauvenet AR, Kelly KM, Cole PD. Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2014;61(4):579-586. doi:10.1002/pbc.24851 - DOI - PubMed
    1. Smeland K, Holte H, Fagerli UM, et al. . Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life. Haematologica. 2022;107(11):2698-2707. doi:10.3324/haematol.2021.280413 - DOI - PMC - PubMed
    1. Keller FG, Castellino SM, Chen L, et al. . Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: A report from the Children’s Oncology Group. Cancer. 2018;124(15):3210-3219. doi:10.1002/cncr.31519 - DOI - PMC - PubMed
    1. Parekh A, Keller FG, McCarten KM, et al. . Targeted radiotherapy for early-stage, low-risk pediatric Hodgkin lymphoma slow early responders: a COG AHOD0431 analysis. Blood. 2022;140(10):1086-1093. doi:10.1182/blood.2022016098 - DOI - PMC - PubMed
    1. Daw S, Cole PD, Hoppe BS, et al. . Transplant-free approach in relapsed Hodgkin lymphoma in children, adolescents, and young adults: a nonrandomized clinical trial. JAMA Oncol. Published online January 2, 2025. doi:10.1001/jamaoncol.2024.5627 - DOI - PMC - PubMed

LinkOut - more resources